| Author | Gandelman, Juliana de Fátima Santos | |
| Author | Rodrigues, Marcio Lourenço | |
| Author | Silva, Alice Machado | |
| Access date | 2019-01-11T16:49:52Z | |
| Available date | 2019-01-11T16:49:52Z | |
| Document date | 2018 | |
| Citation | SANTOS-GANDELMAN, Juliana; RODRIGUES, Márcio Lourenço; SILVA, Alice Machado. Future perspectives for cryptococcosis treatment. Expert Opinion on Therapeutic Patents, v. 28, n. 8, p. 625-634, 2018. | pt_BR |
| ISSN | 1354-3776 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/30987 | |
| Language | eng | pt_BR |
| Publisher | Taylor & Francis Group | pt_BR |
| Rights | restricted access | pt_BR |
| Subject in Portuguese | Patente | pt_BR |
| Subject in Portuguese | Prospecção tecnológica | pt_BR |
| Title | Future perspectives for cryptococcosis treatment | pt_BR |
| Type | Article | |
| DOI | 10.1080/13543776.2018.1503252 | |
| Abstract | Cryptococcosis is one of the most devastating human fungal infections. Despite its impact, none of the standard antifungals were developed after 1990. New, improved, less toxic, affordable and widely available treatment is, therefore, imperative. Areas covered: This review offers an insight into technological developments for cryptococcosis disclosed in patent literature. From a broad search of patent documents claiming cryptococcosis treatment and having earliest priority between 1995 and 2015, we selected and summarized compounds/molecules (i) revealed in documents disclosing in vivo activity against Cryptococcus spp. or (ii) found in the pipeline of companies that appeared as assignees in our patent search. This information was complemented with data on compounds under development for this indication from the database Integrity (Clarivate Analytics). Expert opinion: This review demonstrates that drug development against cryptococcosis is discrete. However, it also shows that the existing development is not focused on a single class of molecules, but on different types of molecules with distinct fungal targets, reflecting the complexity of generating novel anti-cryptococcal tools. Given the intrinsic difficulties and high costs of drug development and the evident market failure in this field, we consider drug repurposing the most promising avenue for cryptococcosis treatment. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil / Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças Negligenciadas. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças Negligenciadas. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Subject | Antifungals | pt_BR |
| Subject | Cryptococcosis | pt_BR |
| Subject | Cryptococcus | pt_BR |
| Subject | Patent landscape | pt_BR |
| Embargo date | 2022-01-01 | |
